Wyost (denosumab-bddz) Injection, 120 mg Single-Dose Vial, 1.7 mL
Wyost is a RANK ligand (RANKL) inhibitor biosimilar to Prolia/Xgeva, supplied as a sterile, preservative-free solution for subcutaneous injection. Each single-dose vial contains 120 mg of denosumab-bddz in 1.7 mL (70 mg/mL). It is indicated for the treatment of osteoporosis and for the prevention of skeletal-related events in patients with bone metastases.
Vendor Pricing Comparison
Sorted by lowest price · Add now, sign in at checkout
Vendor Pricing Comparison
Sorted by lowest price · Add now, sign in at checkout
Wyost is a RANK ligand (RANKL) inhibitor biosimilar to Prolia/Xgeva, supplied as a sterile, preservative-free solution for subcutaneous injection. Each single-dose vial contains 120 mg of denosumab-bddz in 1.7 mL (70 mg/mL). It is indicated for the treatment of osteoporosis and for the prevention of skeletal-related events in patients with bone metastases.
1 vendor
